文献速递生殖医学

在个体化激素剂量算法中加入抗苗勒管激素未能改善卵巢反应预测——一项随机对照试验

The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
PubMed 文献 · Hum Reprod · 2017-01-01

研究将308例首次接受IVF治疗的患者随机分为两组,比较在剂量算法中加入AMH(干预组)与仅用AFC、年龄和BMI(对照组)对目标卵巢反应率的影响。结果显示两组目标获卵数(5-12个)比例无显著差异,干预组低反应周期更多,但取消周期率及中重度OHSS发生率无差异。

要点

  • 在剂量算法中加入AMH未提高目标获卵数(5-12个)的患者比例。
  • 干预组低反应(<5个卵母细胞)周期比例高于对照组(25.7% vs 11.0%,P<0.01)。
  • 两组取消周期率及中重度OHSS发生率无显著差异。

核心结论

  • 在未选择的患者人群中,与不含AMH的剂量方案相比,包含AMH的个体化剂量方案未改变达到目标获卵数的女性人数、因低反应取消周期率或中重度OHSS发生率。
  • 本研究无法回答使用FSH剂量决策算法是否优于标准剂量,也无法回答哪种卵巢储备试验最有效。

研究设计与样本

  • 2013年1月至2016年5月,308例开始首次IVF治疗的患者通过计算机随机化程序按1:1比例随机分配至两种剂量算法组,分配隐藏,患者和治疗医生设盲。
  • 干预组算法包括AMH、AFC、年龄和BMI;对照组算法仅包括AFC、年龄和BMI。
  • 研究为单中心研究,在一所大学医院的大型IVF单位进行。
  • 纳入年龄>18且<40岁、BMI>18.0且<35.0 kg/m2、计划进行标准IVF的首次IVF周期女性。
  • 所有患者采用GnRH激动剂方案,使用重组FSH进行刺激。

主要发现

  • 目标获卵数(5-12个)的患者比例:干预组81/152(53.3%)vs 对照组96/155(61.9%)(P=0.16,差值-8.6,95%CI:-20.3至3.0)。
  • 低反应(<5个卵母细胞)周期:AMH组39/152(25.7%)vs 非AMH组17/155(11.0%)(P<0.01)。
  • 因低反应取消周期:7/152(4.6%)vs 4/155(2.6%)(P=0.52)。
  • 过度反应(>12个卵母细胞):32/152(21.1%)vs 42/155(27.1%)(P=0.27)。
  • 中重度OHSS:5/152(3.3%)vs 6/155(3.9%)(P=1.0);每启动周期活产率:48/152(31.6%)vs 42/155(27.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • AMH值分为预测低、正常和高反应者的分类最初使用Diagnostic Systems Laboratories检测建立,后被转换为更新近发布的检测,缺乏国际标准和公认的参考区间。
  • 不同检测方法之间AMH值的解读应谨慎。
  • 本研究无法回答使用FSH剂量决策算法是否优于标准剂量,也无法回答哪种卵巢储备试验最有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the addition of anti-Müllerian hormone (AMH) to a conventional dosage regimen, including age, antral follicle count (AFC) and BMI, improve the rate of targeted ovarian response, defined as 5-12 oocytes after IVF? SUMMARY ANSWER: The addition of AMH did not alter the rate of targeted ovarian response, 5-12 oocytes, or decreased the rate of ovarian hyperstimulation syndrome (OHSS) or cancelled cycles due to poor ovarian response. WHAT IS KNOWN ALREADY: Controlled ovarian hyperstimulation (COH) in connection with IVF is sometimes associated with poor ovarian response resulting in low pregnancy and live birth rates or leading to cycle cancellations, but also associated with excessive ovarian response, causing an increased risk of OHSS. Even though it is well-established that both AMH and AFC are strong predictors of ovarian response in IVF, few randomized trials have investigated their impact on achieving an optimal number of oocytes. STUDY DESIGN, SIZE AND DURATION: Between January 2013 and May 2016, 308 patients starting their first IVF treatment were randomly assigned, using a computerized randomization program with concealed allocation of patients and in the proportions of 1:1, to one of two dosage algorithms for decisions on hormone starting dose, an algorithm, including AMH, AFC, age and BMI (intervention group), or an algorithm, including only AFC, age and BMI (control group). The study was blinded to patients and treating physicians. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged >18 and <40 years, with a BMI above 18.0 and below 35.0 kg/m2 starting their first IVF cycle where standard IVF was planned, were eligible. All patients were treated with a GnRH agonist protocol and recombinant FSH was used for stimulation. The study was performed as a single-centre study at a large IVF unit at a university hospital. MAIN RESULTS AND THE ROLE OF CHANCE: The rate of patients having the targeted number of oocytes retrieved was 81/152 (53.3%) in the intervention group versus 96/155 (61.9%) in the control group (P = 0.16, difference: -8.6, 95% CI: -20.3; 3.0). Cycles with poor response (<5 oocytes) were more frequent in the AMH group, 39/152 (25.7%) versus the non-AMH group, 17/155 (11.0%) (P < 0.01), while the number of cancelled cycles due to poor ovarian response did not differ 7/152 (4.6%) and 4/155 (2.6%) (P = 0.52). An excessive response (>12 oocytes) was seen in 32/152 (21.1%) and 42/155 (27.1%) patients, respectively (P = 0.27). Moderate or severe OHSS was observed among 5/152 (3.3%) and 6/155 (3.9%) patients, respectively (P = 1.0). Live birth rates were 48/152 (31.6%) and 42/155 (27.1%) per started cycle. LIMITATIONS, REASONS FOR CAUTION: The categorization of AMH values in predicted low, normal and high responders was originally established using the Diagnostic Systems Laboratories assay and was translated to more recently released assays, lacking international standards and well-established reference intervals. The interpretation of AMH values between different assays should therefore be made with some caution. WIDER IMPLICATIONS OF THE FINDINGS: An individualised dosage regimen including AMH compared with a non-AMH dosage regimen in an unselected patient population did not alter the number of women achieving the targeted number of oocytes, or the cancellation rate due to poor response or the occurrence of moderate/severe OHSS. However, this study cannot answer the question if using an algorithm for dose decision of FSH is superior to a standard dose and neither which ovarian reserve test is the most effective. STUDY FUNDING/COMPETING INTEREST: Financial support was received through Sahlgrenska University Hospital (ALFGBG-70 940) and unrestricted grants from Ferring Pharmaceuticals and the Hjalmar Svensson Research Foundation. None of the authors declares any conflict of interest. TRIAL REGISTRATION: The study was registered at www.clinicaltrials.gov NCT02013973. TRIAL REGISTRATION DATE: 6 December 2013. DATE OF FIRST PATIENT RANDOMIZED: 14 January 2013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Magnusson Å, Nilsson L, Oleröd G, et al. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial. Hum Reprod. 2017. PMID: 28175316. doi:10.1093/humrep/dex012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。